Mon, Jan. 19, 5:11 PM
- As expected, the European Commission approves Novartis' (NYSE:NVS) Cosentyx (secukinumab) as a first-line systemic treatment for adult patients with moderate-to-severe psoriasis. It is the first interleukin-17A inhibitor cleared in Europe.
- Cosentyx is also cleared for sale in Australia and Japan. FDA approval is imminent considering the unanimous positive vote by the Dermatologic and Ophthalmic Drugs Advisory Committee in October.
- Previously: Europe Ad Comm gives thumbs up to Novartis psoriasis drug (Nov. 21, 2014)
- Previously: Ad Comm backs approval of secukinumab (Oct. 21, 2014)
- Psoriasis-related tickers: (NYSE:JNJ) (NASDAQ:DERM) (NYSE:MRK) (NASDAQ:CELG) (NASDAQ:IDRA) (NYSE:HSP) (NYSEMKT:CANF) (NASDAQ:AMGN) (NYSE:AZN) (NYSE:PFE)
Thu, Jan. 15, 8:40 AM
- "Words fail me," says Swatch (OTCPK:SWGAY) CEO Nick Hayek. "Today's SNB action is a tsunami; for the export industry and for tourism, and finally for the entire country." Swatch is lower by 15.75% in European action.
- Previously: Swiss shares crater after SNB abandons cap on euro (Jan. 15)
- A sampling of others: Cement maker Holcim (OTCPK:HCMLY) is down 11.2%, Novartis (NYSE:NVS) is down 9%, Roche (OTCQX:RHHBY) is down 7.9%, Credit Suisse (NYSE:CS) is down 11.7%, and UBS (NYSE:OUBS) is down 10.8%.
- The good news for ADR players is that's all action in Switzerland. Thanks to the franc's now 13.5% gain, the ADRs trading in the U.S. are likely all to be higher.
Thu, Jan. 15, 8:35 AM
- Swiss-based Novartis (NYSE:NVS) jumps 5% premarket in response to the upsurge in the value of the Swiss franc versus the euro. The franc rose 30% after the Swiss National Bank announced that it would remove the three-year old cap of 1.20 francs/euro.
- Previously: Swiss shares crater after SNB abandons cap on euro (Jan. 15)
Thu, Jan. 15, 7:22 AM
- In an effort to increase its focus on developing new drugs, privately-held Boehringer Ingelheim says that it is considering the sale of Roxane Labs, its U.S.-based generics unit. The company believes it makes more sense for a generics specialist to own the 1,300-employee business.
- The generics industry is fiercely competitive as the number of blockbuster drugs coming off patent has declined from its peak in 2012. The top players are (NYSE:TEVA), Sandoz (NYSE:NVS) and Actavis (NYSE:ACT).
- According to Bloomberg, Roxane could fetch as much as $2.4B. Morgan Stanley is advising.
Wed, Jan. 14, 12:02 PM| Comment!
Wed, Jan. 14, 9:13 AM
- Express Scripts' (NASDAQ:ESRX) success in containing the prices of new HCV therapies by pitting Gilead Sciences (NASDAQ:GILD) against AbbVie (NYSE:ABBV) is sending shock waves through the biotech/pharma industry. Most of the big players slumped yesterday as investors fear that ESRX's tactics will spread to other high cost areas like cancer and cholesterol.
- At JPM15 yesterday, CEO George Paz said that the new cholesterol-lowering post-statin PCSK9 inhibitors will be the next big opportunity to pit drug firms against each other in order to drive costs down. FDA clearance of the first two therapies, one from Amgen (NASDAQ:AMGN) and the other from Regeneron Pharmaceuticals (NASDAQ:REGN) (NYSE:SNY), is expected to occur at about the same time.
- The prices of emerging cancer therapies will also be in payers' crosshairs. Amgen's Blincyto, for example, costs $178,000 per standard course of treatment while Merck's (NYSE:MRK) Keytruda is close behind at $150,000.
- Related tickers: (NYSE:AZN) (NYSE:GSK) (NYSE:LLY) (ABBV) (NYSE:PFE) (NASDAQ:BIIB) (NYSE:ABT) (NASDAQ:CELG) (NYSE:BMY) (OTCQX:RHHBY) (NYSE:JNJ) (NYSE:NVS) (OTCPK:BAYRY)
Wed, Jan. 14, 8:25 AM
- Ziopharm (NASDAQ:ZIOP) jumps 50% premarket on robust volume in response to its announcement of an exclusive license deal with partner Intrexon (NYSE:XON) (+12%) with The University of Texas MD Anderson Cancer Center covering technology and intellectual property related to non-viral adoptive cellular cancer immunotherapies. The technologies originate from two researchers who have pioneered the design and clinical investigation of chimeric antigen receptor (CAR) T cell therapies for the potential treatment of cancer using non-viral gene integration platforms.
- The two researchers are Laurence Cooper, M.D., Ph.D, professor of pediatrics at MD Anderson who has expertise in immunotherapies and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota, who discovered and developed a system called Sleeping Beauty, a non-viral DNA plasmid-based gene transfer system.
- The deal brings the CAR-T technology together Intrexon's technology suite and Ziopharm's clinically tested RheoSwitch Therapeutic System interleukin-12 modules. Up to five CARs are expected to enter the clinic this year and off-the-shelf programming initiating in 2016.
- Under the terms of the agreement, MD Anderson will receive $100M from the companies in the form of $50M of common stock from each firm. In addition, the companies have committed $15M - 20M over each of the next three years for researching and developing the technologies.
- CAR-T therapies are the "next big thing" in cancer treatment.
- Related tickers: (NASDAQ:KITE) (NASDAQ:JUNO) (NASDAQ:AMGN) (NYSE:NVS) (NYSE:JNJ)
Mon, Jan. 12, 7:25 AM
- With the goal of taking a leadership role in introducing mobile and digital technologies that have the potential of changing the practice of medicine, Novartis (NYSE:NVS) and Qualcomm Ventures form a joint investment company to support emerging firms with technologies, products or services that "go beyond the pill."
- Novartis Pharmaceuticals Division Head David Epstein says, "We are excited by the potential of digital medicines to further enhance our mission of the right drug for the right patient at the right time helping people live longer with a better quality of life giving more time to do the things that matter to them."
- No specific terms of the partnership are disclosed.
Thu, Jan. 8, 8:39 AM
- Novartis (NYSE:NVS) files two New Drug Applications (NDA) with the FDA for medicines (QVA149 and NVA237) for the treatment of chronic obstructive pulmonary disease (COPD) after both Phase 3 programs achieved their safety and efficacy endpoints.
- The first Phase 3 study, called Expedition, evaluated twice-daily doses of QVA149 (indacaterol/glycopyrronium bromide) compared to its monotherapy components in patients with moderate-to-severe COPD as measured by FEV1 at Week 12. The product is intended as maintenance treatment to relieve the symptoms in adult patients with COPD.
- The other Phase 3 program, GEM, assessed twice-daily doses of NVA237 (glycopyrronium bromide) versus placebo in patients with moderate-to-severe COPD measured by FEV1 at Week 12. The product is intended for the maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
- The safety trials, Flight 3 and GEM 3, achieved their endpoints.
- Both product candidates have been submitted for U.S. registration only. Outside of the U.S., QVA149 is marketed as Ultibro Breezhaler while NVA237 is marketed as Seebri Breezhaler.
Wed, Jan. 7, 9:52 PM
- The FDA's Oncologic Drugs Advisory Committee recommends the approval of Sandoz's (NYSE:NVS) biosimilar to Amgen's Neupogen (filgrastim) including all indications on Neupogen's label.
- If approved, which seems virtually certain at this point, Sandoz will market the product under the brand name Zarxio.
- Previously: Ad Comm approaches for Neupogen biosimilar (Jan. 5)
Wed, Jan. 7, 8:22 AM
- Novartis (NYSE:NVS) inks a license and collaboration agreement with Intellia Therapeutics for the discovery and development of new drugs utilizing CRISPR genome editing technology and Caribou Biosciences for the development of drug discovery tools.
- Clustered regularly interspaced short palindromic repeats, or CRISPR, enables the easy and precise editing of the genes of targeted cells. It is a powerful tool for creating very specific disease models in drug discovery and has substantial potential as a therapeutic modality for treating disease at the genetic level.
- R&D activities will focus on the use of CRISPR ex vivo to engineer chimeric antigen receptor T cells (CARTs) and hematopoietic stem cells (HSCs).
- Under the terms of the agreement with Intellia, Novartis receives exclusive rights to develop all collaboration programs focused on engineered CARTs and the right to develop an undisclosed number of targets for ex vivo editing of HSCs. It also receives non-exclusive rights for limited in vivo therapeutic applications of CRISPR systems.
- Novartis will increase its equity investment in Intellia, make an upfront payment and provide technology access fees and R&D funding during the five-year term of the contract. Intellia is eligible to receive development-based milestones and royalties on commercial sales.
- Under the terms of the agreement with Caribou, Novartis receives non-exclusive rights to Caribou's CRISPR platform for research conducted during the collaboration and will fund the one-year research program. It will also make an equity investment in Caribou.
Tue, Jan. 6, 8:18 PM
Mon, Jan. 5, 2:00 PM
- The FDA's Oncologic Drugs Advisory Committee meets Wednesday to review the Biologics License Application (BLA) submitted by Sandoz (NVS +0.1%) for a biosimilar version of Amgen's (AMGN -0.8%) Neupogen (filgrastim).
- In the briefing documents, reviewers determined that there are no clinically meaningful differences compared to Neupogen. This bodes well for the approval of the first biosimilar in the U.S.
- Briefing doc
Thu, Jan. 1, 9:27 AM
- Novartis (NYSE:NVS) has completed the $5.4B sale of its animal-health division to Eli Lilly (NYSE:LLY).
- The sale of the unit is part of a complex overhaul at NVS that will focus the company on three core businesses: innovative pharmaceuticals, eye care, and generics.
- As a result of the transaction, Novartis will record an exceptional pretax gain of about $4.6B in Q1 of 2015.
Dec. 26, 2014, 11:54 AM
- The Japanese Ministry of Health, Labour and Welfare approves Novartis' (NVS +0.1%) Cosentyx (secukinumab) for the treatment of adult patients with psoriasis vulgaris and psoriatic arthritis who are not adequately responding to systemic therapies, except for biologics.
- Secukinumab inhibits IL-17A, a proinflammatory cytokine that is activated by T cells.
- Regulatory approvals in the U.S. and Europe are pending.
- Previously: Europe Ad Comm gives thumbs up to Novartis psoriasis drug (Nov. 21)
- Previously: Ad Comm backs approval of secukinumab (Oct. 21)
Dec. 23, 2014, 7:20 AM
- The European Commission approves Alcon's (NYSE:NVS) Travatan (travaprost ophthalmic solution) to decrease elevated intraocular pressure in pediatric patients, aged two months to less than 18 years, with ocular hypertension or pediatric glaucoma.
- Travatan is currently indicated to decrease elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma.
- Pediatric glaucoma is responsible for 5% of childhood blindness worldwide. There is no cure for glaucoma and, if vision is lost, it cannot be restored.
NVS vs. ETF Alternatives
Other News & PR